Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—The diagnostics division of Siemens Healthcare announced the launch of three scalable hematology systems: the Advia 360 System, Advia 560 System, and Advia 560 AL System. These lower-capacity systems offer testing capabilities for small to mid-size laboratories and may also be used as backup systems for larger laboratories.
May 2015—Seegene announced that the Food and Drug Administration has granted 510(k) market clearance for its TOCE-based herpes simplex virus types 1 and 2 assay. This is the first product Seegene has taken through the FDA, and it opens the way for the company’s other planned FDA submissions of multiplex real-time PCR reagents.
May 2015—Myriad RBM launched immunoassay services based on Quanterix’s ultrasensitive Simoa (single molecule array) platform, which enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
May 2015—The diagnostics division of Siemens Healthcare announced the availability of two urine testing solutions for U.S. central laboratories—the Clinitek Novus Automated Urine Chemistry Analyzer and the Clinitek AUWi Pro Automated Urine Workstation.
May 2015—Thermo Fisher Scientific and Samsung Electronics have formed a strategic collaboration to jointly design, develop, and market new point-of-care solutions in key applications, such as the detection of sepsis, drugs of abuse, and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
May 2015—The Clinical and Laboratory Standards Institute has published a new document, “Process Management (QMS18-Ed1).” This guideline describes four requirements for managing laboratory processes and provides suggestions for effectively meeting regulatory and accreditation requirements, optimizing efficient use of resources, and contributing to patient safety and positive outcomes.
May 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and can be incorporated as a reflex test measure following abnormal Pap smear results.
May 2015—Seegene announced that Health Canada has approved its six-target Allplex Respiratory Panel 5 assay, which identifies influenza virus A and B, RSV A and B, and influenza A virus subtypes H1 and H3.
May 2015—WaveSense, a manufacturer of in vitro diagnostic cell targeting, enrichment, and isolation products for pathology, urology, and oncology, added a product to its line of cell enrichment applications delivered through its patented EpiSep medical product line.
May 2015—EKF Diagnostics has introduced the Stanbio Chemistry Glycated Serum Protein LiquiColor test, a diabetic biomarker test that provides a two- to three-week indicator of average blood glucose, closing the information gap between daily blood glucose testing and the two- to three-month HbA1c reading. GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan, and hemodialysis.
